Latest Articles

Publication Date
Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval - Corsicana Daily Sun

Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval Corsicana Daily Sun

Published: Aug. 4, 2026, 1:02 p.m.
Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval - Voice of Alexandria

Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval Voice of Alexandria

Published: Aug. 4, 2026, 1:02 p.m.
Comment on "Dienogest Therapy against the Combined Oral Contraceptive Pill in Deep Infiltrating Endometriosis Cases: A Systematic Review and Meta-Analysis".

Published: July 17, 2026, midnight
Adjunctive vitamin D supplementation in women receiving dienogest therapy for endometriosis: a randomized controlled trial.

Endometriosis is a chronic, estrogen-dependent inflammatory disease that causes debilitating pain and significantly impairs quality of life. Due to its anti-inflammatory and immunomodulatory properties, vitamin D has been proposed as …

Published: July 16, 2026, midnight
Comparative effectiveness of hormonal therapies for preventing recurrence in endometriosis: a real-world retrospective cohort study with risk factor analysis.

Endometriosis is a common chronic disease in women of reproductive age, and long-term postoperative medical management is a key strategy for preventing recurrence. Currently used clinical medications include dienogest (DNG), …

Published: June 30, 2026, midnight
Evaluation of the use of dienogest in women with deep endometriosis and ovarian endometrioma: a retrospective cohort study.

The aim of this study was to evaluate the use of dienogest in the treatment of deep endometriosis and ovarian endometrioma.

Published: June 22, 2026, midnight
Epidemiology, Risk Factors, Diagnosis, and Comorbidities of Endometriosis: An Umbrella Review.

Background: Endometriosis is a chronic estrogen-dependent inflammatory disease estimated to affect up to 190 million women of reproductive age worldwide based on clinical and population-based estimates, although only 22.3 million …

Published: June 12, 2026, midnight
Dienogest-associated capillaroscopic abnormalities: a case report and narrative review of progestin microvascular effects.

Progestins are widely used for endometriosis with proven efficacy and favorable safety. Their microvascular effects, however, are not fully understood. We report a 35-year-old woman who developed recurrent hand erythema …

Published: May 25, 2026, midnight
Efficacy of different pretreatments in IVF outcomes in patients with endometriosis: A systematic review and network meta‑analysis.

To investigate the efficacy of different pretreatment protocols for women with endometriosis undergoing IVF. We systematically searched the Cochrane Library, PubMed, Medline, and Embase from inception to April 30, 2025, …

Published: May 18, 2026, midnight
Efficacy and Safety of Elagolix Versus Dienogest for Treatment of Moderate-to-Severe Endometriosis Pain: A Phase III, Multicentric, Double-Blind, Active-Controlled, Non-Inferiority Study.

To compare the efficacy, safety and tolerability of elagolix with dienogest in women with moderate-to-severe endometriosis-associated pain.

Published: May 11, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!